ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Thermo Fisher goes in on a biologics facility in China

by Rick Mullin
November 14, 2020 | APPEARED IN VOLUME 98, ISSUE 44

 

Seeing increasing demand for biologic drugs in China, Thermo Fisher Scientific has formed a joint venture with Innoforce Pharmaceuticals, a biologic-drug services firm in Hangzhou, China, aimed at establishing a biologic-and-sterile-drug development and manufacturing facility in Hangzhou by 2022. Earlier this year, Thermo Fisher opened a bioprocess development services center at its Saint Louis biologics complex. Thermo Fisher has said it plans to spend more than $475 million on biopharmaceutical capabilities and capacity this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment